Literature DB >> 16365741

HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.

José A Campillo1, Jorge A Martínez-Escribano, Manuel Muro, Rosa Moya-Quiles, Luis A Marín, Olga Montes-Ares, Natalia Guerra, Paloma Sánchez-Pedreño, José F Frías, José A Lozano, Ana M García-Alonso, M Rocío Alvarez-López.   

Abstract

Available data have led to a controversy on the relationship between human leukocyte antigen (HLA) and cutaneous malignant melanoma susceptibility or prognosis. Moreover, the influence of HLA-C on melanoma has not yet been well established. Therefore, the aim of the current study was to analyze the possible influence of the HLA system on melanoma susceptibility and prognosis in the Spanish population. For this purpose, HLA-A and HLA-B serotyping and HLA-C, HLA-DRB1, and HLA-DQB1 genotyping by polymerase chain reactions using sequence-specific oligonucleotide (PCR-SSO) and sequence-specific primer (PCR-SSP) were performed in 174 melanoma patients and 227 ethnically matched controls. The number of controls was increased up to 356 for HLA-C typing. Patients were stratified according to the histological subtypes of melanoma, sentinel lymph node status, tumor thickness, and ulceration of primary lesion. No HLA-A, HLA-B, HLA-DRB1, or HLA-DQB1 relationship with melanoma was observed for susceptibility or disease prognosis. However, the analysis of HLA-C locus showed that individuals homozygous for HLA-C(Lys80) were significantly more frequent within the patient than the control group. Remarkably, individuals homozygous for group 2 HLA-C alleles (HLA-C(Lys80)) seem to be associated with metastatic progression of melanoma. In contrast, we found a negative association between group 1 HLA-C alleles (HLA-C(Asn80)) and disease susceptibility or metastasis development. In conclusion, although an association with HLA-A, HLA-B, HLA-DRB1, or HLA-DQB1 was not demonstrated, the study of the HLA-C locus revealed that the analysis of the dimorphism at position 80 in the alpha1 helix may help to evaluate the risk and prognosis of melanoma in our population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16365741     DOI: 10.1007/s00251-005-0065-2

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  49 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.

Authors:  H Benlalam; N Labarrière; B Linard; L Derré; E Diez; M C Pandolfino; M Bonneville; F Jotereau
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

Review 3.  Natural killer cells: from no receptors to too many.

Authors:  L L Lanier
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

4.  Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma.

Authors:  T Kageshita; T Naruse; S Hirai; T Ono; T Horikoshi; H Nakagawa; K Tamaki; K Hayashibe; M Ichihashi; J Nakayama; Y Hori; A Ozawa; M Miyahara; M Ohkido; H Inoko
Journal:  Tissue Antigens       Date:  1997-05

Review 5.  From defined human tumor antigens to effective immunization?

Authors:  T Boon; T F Gajewski; P G Coulie
Journal:  Immunol Today       Date:  1995-07

6.  Increase of HLA-DR4 in melanoma patients from Alabama.

Authors:  B O Barger; R T Acton; S J Soong; J Roseman; C Balch
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

7.  Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.

Authors:  R Zennadi; Z Abdel-Wahab; H F Seigler; T L Darrow
Journal:  Cell Immunol       Date:  2001-06-15       Impact factor: 4.868

8.  Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors.

Authors:  M Valés-Gómez; H T Reyburn; R A Erskine; J Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

9.  In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.

Authors:  A Kikuchi; M Nieda; C Schmidt; Y Koezuka; S Ishihara; Y Ishikawa; K Tadokoro; S Durrant; A Boyd; T Juji; A Nicol
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

10.  A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.

Authors:  J Herman; P van der Bruggen; I F Luescher; S Mandruzzato; P Romero; J Thonnard; K Fleischhauer; T Boon; P G Coulie
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

View more
  6 in total

1.  Antigenic Hsp70-peptide upregulate altered cell surface MHC class I expression in TAMs and increases anti-tumor function in Dalton's lymphoma bearing mice.

Authors:  Pramod Kumar Gautam; Arbind Acharya
Journal:  Tumour Biol       Date:  2014-11-28

2.  Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.

Authors:  Sarah Samandary; Hédia Kridane-Miledi; Jacqueline S Sandoval; Zareen Choudhury; Francina Langa-Vives; Doran Spencer; Aziz A Chentoufi; François A Lemonnier; Lbachir BenMohamed
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

3.  KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.

Authors:  José A Campillo; Isabel Legaz; M Rocío López-Álvarez; José Miguel Bolarín; Beatriz Las Heras; Manuel Muro; Alfredo Minguela; María R Moya-Quiles; Rosa Blanco-García; Helios Martínez-Banaclocha; Ana M García-Alonso; M Rocío Alvarez-López; Jorge A Martínez-Escribano
Journal:  Immunogenetics       Date:  2013-01-31       Impact factor: 2.846

4.  Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility.

Authors:  Alexander J Stratigos; Paola Ghiorzo; Kevin M Brown; Susana Puig; Eduardo Nagore; Maria Teresa Landi; D Timothy Bishop; Stuart MacGregor; Mitchell J Machiela; Myriam Brossard; Donato Calista; Jiyeon Choi; Maria Concetta Fargnoli; Tongwu Zhang; Monica Rodolfo; Adam J Trower; Chiara Menin; Jacobo Martinez; Andreas Hadjisavvas; Lei Song; Irene Stefanaki; Richard Scolyer; Rose Yang; Alisa M Goldstein; Miriam Potrony; Katerina P Kypreou; Lorenza Pastorino; Paola Queirolo; Cristina Pellegrini; Laura Cattaneo; Matthew Zawistowski; Pol Gimenez-Xavier; Arantxa Rodriguez; Lisa Elefanti; Siranoush Manoukian; Licia Rivoltini; Blair H Smith; Maria A Loizidou; Laura Del Regno; Daniela Massi; Mario Mandala; Kiarash Khosrotehrani; Lars A Akslen; Christopher I Amos; Per A Andresen; Marie-Françoise Avril; Esther Azizi; H Peter Soyer; Veronique Bataille; Bruna Dalmasso; Lisa M Bowdler; Kathryn P Burdon; Wei V Chen; Veryan Codd; Jamie E Craig; Tadeusz Dębniak; Mario Falchi; Shenying Fang; Eitan Friedman; Sarah Simi; Pilar Galan; Zaida Garcia-Casado; Elizabeth M Gillanders; Scott Gordon; Adele Green; Nelleke A Gruis; Johan Hansson; Mark Harland; Jessica Harris; Per Helsing; Anjali Henders; Marko Hočevar; Veronica Höiom; David Hunter; Christian Ingvar; Rajiv Kumar; Julie Lang; G Mark Lathrop; Jeffrey E Lee; Xin Li; Jan Lubiński; Rona M Mackie; Maryrose Malt; Josep Malvehy; Kerrie McAloney; Hamida Mohamdi; Anders Molven; Eric K Moses; Rachel E Neale; Srdjan Novaković; Dale R Nyholt; Håkan Olsson; Nicholas Orr; Lars G Fritsche; Joan Anton Puig-Butille; Abrar A Qureshi; Graham L Radford-Smith; Juliette Randerson-Moor; Celia Requena; Casey Rowe; Nilesh J Samani; Marianna Sanna; Dirk Schadendorf; Hans-Joachim Schulze; Lisa A Simms; Mark Smithers; Fengju Song; Anthony J Swerdlow; Nienke van der Stoep; Nicole A Kukutsch; Alessia Visconti; Leanne Wallace; Sarah V Ward; Lawrie Wheeler; Richard A Sturm; Amy Hutchinson; Kristine Jones; Michael Malasky; Aurelie Vogt; Weiyin Zhou; Karen A Pooley; David E Elder; Jiali Han; Belynda Hicks; Nicholas K Hayward; Peter A Kanetsky; Chad Brummett; Grant W Montgomery; Catherine M Olsen; Caroline Hayward; Alison M Dunning; Nicholas G Martin; Evangelos Evangelou; Graham J Mann; Georgina Long; Paul D P Pharoah; Douglas F Easton; Jennifer H Barrett; Anne E Cust; Goncalo Abecasis; David L Duffy; David C Whiteman; Helen Gogas; Arcangela De Nicolo; Margaret A Tucker; Julia A Newton-Bishop; Ketty Peris; Stephen J Chanock; Florence Demenais; Jianxin Shi; Mark M Iles; Matthew H Law
Journal:  Nat Genet       Date:  2020-04-27       Impact factor: 38.330

5.  A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment.

Authors:  Rongzhi Huang; Min Mao; Yunxin Lu; Qingliang Yu; Liang Liao
Journal:  Aging (Albany NY)       Date:  2020-04-20       Impact factor: 5.682

6.  HLA-DRB116:01 and HLA-DQB105:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.

Authors:  Xu Wang; Francisco Almazan; Yoel Genaro Montoyo-Pujol; Antonia Martin-Casares; Aurelio Martin; Teresa Cabrera; Miguel Angel López-Nevot
Journal:  J Oncol       Date:  2021-09-30       Impact factor: 4.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.